Enhancing the CDC Autocidal Gravid Ovitrap to control dengue vectors.
This grant opportunity is focused on developing improvements to the Autocidal Gravid Ovitrap (AGO) used for controlling Aedes aegypti mosquitoes, which spread dengue and other arboviruses. It seeks Phase I Small Business Innovation Research (SBIR) proposals, with a funding limit of up to $243,500 for a 6-month duration, and a potential Phase II funding of up to $2,045,816 for up to 2 years. Pr…
\nPhase I SBIR proposals will be accepted.\nFast-track proposals will not be accepted.\nPhase I clinical trials will not be accepted.\n\nNumber of anticipated awards: 1\n\nBudget (total costs): Phase I up to $243,500 for up to 6 months; Phase II of up to $2,045,816 and a Phase II duration of up …
Funding Source
Dates
Documents
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers